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Abstract
: In humans, the adrenal glands and gonads undergo distinctBackground
biological events between 6-10 weeks post conception (wpc), such as testis
determination, the onset of steroidogenesis and primordial germ cell
development. However, relatively little is currently known about the genetic
mechanisms underlying these processes. We therefore aimed to generate a
detailed genomic atlas of adrenal and gonad development across these critical
stages of human embryonic and fetal development.
: RNA was extracted from 53 tissue samples between 6-10 wpcMethods
(adrenal, testis, ovary and control). Affymetrix array analysis was performed
and differential gene expression was analysed using Bioconductor. A
mathematical model was constructed to investigate time-series changes across
the dataset. Pathway analysis was performed using ClueGo and cellular
localisation of novel factors confirmed using immunohistochemistry.
: Using this approach, we have identified novel components of adrenalResults
development (e.g.  ,  ) and confirmed the role of  as the mainASB4 NPR3 SRY 
human testis-determining gene. By mathematical modelling time-series data
we have found new genes up-regulated with   in the testis (e.g.  ),SOX9 CITED1
which may represent components of the testis development pathway. We have
shown that testicular steroidogenesis has a distinct onset at around 8 wpc and
identified potential novel components in adrenal and testicular steroidogenesis
(e.g.  ,  ,  ,  ,  ), as well as testisMGARP FOXO4 MAP3K15 GRAMD1B RMND2
biomarkers (e.g.  ). We have also shown that the developing humanSCUBE1
ovary expresses distinct subsets of genes (e.g. ,  ), but OR10G9 OR4D5
enrichment for established biological pathways is limited.
: This genomic atlas is revealing important novel aspects of humanConclusion
development and new candidate genes for adrenal and reproductive disorders.
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Introduction
The development of the adrenal gland and gonads (testes, ovaries) 
are two of the most important embryological events, but relatively 
little is known about the exact mechanisms of these processes in 
humans.
Development of these structures is closely linked as they arise 
from a shared region of intermediate mesoderm in early embryo-
genesis and subsequently have common biological processes, 
such as the ability to synthesise steroid hormones (see Figure 1 for 
an overview).
The primordial adrenal gland arises as a distinct structure at 
around 28 days post-conception (dpc) and undergoes rapid 
growth during late embryonic and early fetal life (Ishimoto & 
Jaffe, 2011). The adrenal cortex develops into definitive and 
fetal zones that can produce steroid hormones (cortisol, aldoster-
one) and large amounts of adrenal androgens, such as dehydroe-
piandrosterone (DHEA) (Miller & Auchus, 2011; Xing et al., 
2015). Chromaffin cells derived from the sympathetic nervous 
system migrate into the developing adrenal gland and later coa-
lesce to form the adrenal medulla, which secretes adrenaline and 
noradrenaline (Figure 1). It has been proposed that the entire 
hypothalamic-pituitary-adrenal (HPA) axis is functionally intact 
during early fetal life (Goto et al., 2006).
In contrast, the developing gonad remains “bipotential” until 
around 41 dpc as it can differentiate into either a testis or ovary 
(Figure 1) (Bashamboo et al., 2017; Svingen & Koopman, 
2013).
Figure 1. Current model of human gonad and adrenal development between Carnegie Stage 13 (CS13) and Fetal Stage 3 (F3). The 
bipotential gonad and adrenal gland both arise from the adrenogonadal primordium around CS13. Sex determination in the bipotential gonad 
occurs between CS17 and CS23 when transient SRY expression promotes the upregulation of genes, including SOX9, in the developing 
testis. Sex differentiation starts with the onset of steroidogenesis around CS23, which results in development of the external genitalia and 
phallic growth (right panel). Ovary-specific genes are thought to suppress male pathway specification. The ovary also supports germ cell 
expansion and entry into meiosis. The fetal adrenal cortex develops into definitive and fetal zones, producing steroid hormones and adrenal 
androgens. Chromaffin cells derived from the sympathetic nervous system migrate into the developing adrenal gland, merging later to form 
the adrenal medulla.
      Amendments from Version 1
We have undertaken further qRTPCR validation of adrenal gene 
expression and include these data as a revised Figure 5b. We 
also include higher power immunohistochemistry of FOXO4 
and NR5A1 in the nuclei of fetal testis Leydig cells as a revised 
Figure 12d. We include a dataset of differential gene expression 
in the testis versus ovary (Dataset 7, OSF). We now include three 
Supplementary Figures of further validation data to show serial 
upregulation of novel genes in the testis with time (qRTPCR, 
Supplementary Figure 1); upregulation of novel steroidogenic 
components with time (qRTPCR and immunohistochemistry, 
Supplementary Figure 2); higher powered adrenal expression 
data for GRAMD1B and RMDN2 in the adrenal gland as well 
as additional negative control data (immunohistochemistry, 
Supplementary Figure 3). Finally, we have extended the 
discussion to include a paragraph outlining several limitations of 
the study and possible future approaches.
See referee reports
REVISED
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In the developing 46,XY embryo, transient expression of the 
testis-determining gene, SRY, on the Y chromosome is believed 
to lead to upregulation of genes such as SOX9 and the process of 
testis determination (Bashamboo et al., 2017; Hanley et al., 
2000; Hiramatsu et al., 2009; Koopman et al., 2016; Sekido & 
Lovell-Badge, 2008). At around 7–8 weeks post conception 
(wpc), Sertoli cells secrete the peptide hormone Anti-Müllerian 
Hormone (AMH, also known as Müllerian Inhibiting Substance, 
MIS) to regress Müllerian structures (uterus and upper vagina). 
Fetal Leydig cells develop and synthesise testosterone. Testo-
sterone stabilises Wolffian structures and stimulates development 
of the external genitalia through its peripheral conversion to dihy-
drotestosterone (Figure 1) (Miller & Auchus, 2011).
Ovary development in the 46,XX embryo was originally thought 
to be a “passive” process that occurs in the absence of SRY and 
other components of the testis-determining pathway. Although 
the morphological changes in the ovary are less striking, data 
from mice and from 46,XX individuals with rare forms of ovotes-
tis development suggest that distinct pathways are up-regulated 
(e.g. RSPO1/WNT4/β-catenin), which may function largely to 
repress testis development (Figure 1) (Bashamboo et al., 2017; 
Beverdam & Koopman, 2006; Bouma et al., 2007; Jameson et al., 
2012; Nef et al., 2005). The ovary also has expansion of primor-
dial germ cells starting towards the end of this early fetal period 
(Fowler et al., 2009).
Given the limited data currently available (Gerrard et al., 2016; 
Houmard et al., 2009; O’Shaughnessy et al., 2007; Ostrer et al., 
2007), we aimed to generate a genomic atlas of human adrenal 
and gonad development between 6 and 10 wpc. This period 
represents a critical window for organogenesis during which 
many key biological events occur in tissue specification and cel-
lular differentiation. This unique dataset is supported by our 
current knowledge of key genetic components in these processes 
and by human conditions affecting adrenal and gonadal function. 
By comparing datasets at different times and in different tissues, 
as well as by mathematical modelling of time series data, several 
novel insights into human adrenal and gonad development are 
emerging.
Methods
Tissue samples
Human embryonic and fetal tissue samples used in this study 
were obtained in collaboration with the MRC/Wellcome Trust-
funded Human Developmental Biology Resource (HDBR). The 
HDBR is a tissue bank regulated by the Human Tissue Authority. 
Samples were collected with appropriate maternal written 
consent and with approval from the NRES Committee London- 
Fulham (REC reference 08/H0712/34+5). Material was obtained 
only from surgical terminations of pregnancy to avoid any poten-
tially interfering effects of anti-progestogens on nuclear receptor 
gene transcription.
All materials were kept on ice and processed rapidly after 
collection. The adrenal glands, gonads and any control tissues 
needed were identified and removed by blunt dissection under a 
dissecting microscope. Samples were immediately immersed 
in RNAlater® (Ambion, Austin, TX, USA) and stored at -20 C. 
The age of the embryonic or fetal sample was calculated based on 
morphological characteristics using published guidelines (Hern, 
1984; O’Rahilly & Müller, 1987) by a single experienced researcher 
(DG) (Supplementary Table 1). Each tissue sample was also 
karyotyped using standard G-banding, to determine the sex of the 
embryo/fetus and also to ensure there were no significant aneuploi-
dies or chromosomal rearrangements present.
A total of 53 different organs between 42 days post conception 
(dpc) (Carnegie Stage 17) and 10 weeks post conception (wpc) 
(Fetal Stage 3) were included in the analysis. This dataset con-
sisted of 17 adrenal glands, 20 testes and 10 ovaries, as well as 6 
“control” samples (46, XY) from spine, brain, muscle, heart, kid-
ney and liver. The adrenal gland and testis samples came from the 
same fetus in 11 cases across the age range. Control samples were 
obtained from 2 of these. An overview of all samples is provided in 
Supplementary Table 1.
RNA extraction
RNA was extracted using the TRIzol method. In brief, the tis-
sue sample was removed from RNAlater® and homogenized in 
1ml TRIzol reagent using a Pellet Pestle micro-grinder (Kontes/ 
Kimble Chase, USA). Chloroform (0.2 ml) was added to allow 
phase separation, and RNA was precipitated from aqueous phase by 
addition of 0.5 ml isopropyl alcohol. The RNA pellet was washed 
in 1ml ice-cold 75% ethanol and air dried before resuspension in 
nuclease-free water. The concentration and A260/A280 ratio 
was measured using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Witec, Littau, Switzerland). RNA was 
stored at -80 C prior to use.
Arrays
Expression assay was performed using the Affymetrix 
GeneChip Human Gene 1.0 ST array, covering approximately 
36000 RefSeq transcripts. In brief, RNA concentration and qual-
ity was assessed using an Agilent Bioanalyzer. 250ng of total 
RNA was converted to ssDNA using the Ambion Whole Tran-
script Sense Target Labeling Assay and labelled and prepared for 
hybridisation using the Affymetrix Genechip WT Terminal 
Labelling and Hybridisation kits, as per the manufacturer’s pro-
tocol. Hybridisation was performed for 16 hours at 45 C. Arrays 
were washed and stained using the Affymetrix Fluidics Station 
450 and scanned on the Affymetrix Genechip 3000S scanner as 
per the manufacturer’s instructions.
After passing quality control, CEL files were normalised using 
the Robust Multi-array Average (RMA) algorithm (oligo pack-
age in R, version 1.38.0). Adjustments for batch effects was per-
formed using ComBat (sva package, version 3.22.0) (Leek et al., 
2012). One adrenal sample that was an extreme outlier in several 
QC platforms was excluded prior to further analysis (leaving the 
17 adrenal samples reported above). Statistical analysis of the 
microarray data was carried out in R programming environment 
(version 3.3.3 running under Ubuntu 16.04.2) using Bioconduc-
tor packages ‘oligo’(Carvalho & Irizarry, 2010) and ‘limma’ 
(version 3.30.12) (Smyth, 2004). The hierarchical cluster dendro-
gram was generated using the agglomeration method ward.D2. 
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Differentially expressed genes were obtained using linear models 
and the Benjamini and Hochberg method was applied to adjust the 
P-values for multiple testing (Benjamini & Hochberg, 1995). The 
cut-off values for adjusted P-values and log2 fold-changes were 
0.05 and 1 or 2, respectively. The pheatmap (version 1.0.8) and 
VennDiagram packages (version 1.6.17) were used to generate the 
heatmaps and Venn diagrams, respectively. Pathway enrichment 
analysis was carried out using the Cytoscape plug-in ClueGO (ver-
sion numbers 3.4.0 and 2.3.3, respectively) (Bindea et al., 2009).
Array data are available from the ArrayExpress database under the 
accession number E-MTAB-5525.
A model of expression changes over time
A phenomenological model (“BALT model”) was developed to 
pinpoint the time when gene expression levels change, as well as 
evaluating the speed and magnitude of this transition. The general 
form of the model is a sigmoid function relating the transcript con-
centration X (on a 2-log scale) to the time elapsed since conception 
(t, expressed in days):
= +
+ ( ) ( – )*
( )
1 f T L t
A
X t B
e
In the formula above, B (“basis”) is the basic expression level 
at the start of the time course and A (“amplitude”) is the ampli-
tude of the difference between the finishing expression level and 
the starting one. For down-regulated genes this latter parameter 
takes negative values. The parameter L (“localisation”) captures 
the inflexion point of the sigmoid, and hence can identify at which 
point in time a gene undergoes a change of expression level. Finally, 
T (“Transition”) is a measure of the speed of this transition and 
the sub-function f was chosen so that this parameter can also be 
expressed in days.
The model was fitted to the data for each gene using a least 
square objective function (maximum likelihood) with a gradient 
following algorithm (Levenberg-Marquardt). With this, the val-
ues for the aforementioned parameters that best fit the data were 
obtained as well as an evaluation of the goodness of fit (and thus, 
of the validity of the model). Furthermore, robustness of the 
parameters were estimated using a Markov Chain Monte Carlo 
procedure.
It was found that most of the differentially expressed genes in 
our biological system could be well described by this model or 
simplified versions of it. Hence the procedure was seen as a way to 
compress high dimensional data into a smaller set of easily inter-
pretable indicators. This modelling framework allowed genes to 
be grouped according to their transition times between different 
expression levels in a developmental process as well as the manner 
of this transition. This model was used predominantly to investi-
gate time course data in the testis. The two main groups of genes 
that were analysed were those that followed a curvilinear upregula-
tion in expression from the start of the dataset similar to SOX9, as 
well as genes that showed a sigmoidal upregulation in expression 
with the onset of steroidogenesis. The mid-point (in dpc) of the 
Carnegie or Fetal Stage was used when analysing data for the 
model (Supplementary Table 1).
Quantitative RT-PCR
Purified RNA from adrenal glands or testis and control tissue (liver, 
brain, muscle) was quantified using the NanoDrop 1000 spectro-
photometer (Thermo Fisher Scientific). First-strand cDNA was 
synthesised using SuperScript II Reverse Transcriptase (Invitrogen) 
and random primers according to the manufacturer’s instructions. 
Taqman® probes were obtained for the following genes of 
interest: MAP3K15, ASB4, TDGF1, FOXO4, NRK, CITED1, 
ZNF280B, PRPS2, ANKRD18A, GRAMD1B and RMDN2 
(Applied Biosystems, Warrington, UK). Amplification was 
performed in a total volume of 20 µl per reaction using 
TaqMan® Gene Expression Master Mix on the StepOnePlus™ 
System (Thermo Fisher Scientific). Three biological replicates were 
used for each group. The relative quantification of gene expression 
was calculated as 2-ΔΔCt using the comparative Ct (ΔΔCt) method 
and GAPDH as the housekeeping internal control. Data were ana-
lysed with StepOne software (v 2.1) and results expressed as fold 
change above control. Standard error of the mean is shown.
Immunohistochemistry
Human adrenal glands and testes of the relevant ages of inter-
est were obtained with approval from the HDBR. Tissues were 
sunk and positioned in Tissue-Tek® O.C.T. (Fisher Scientific, 
Loughborough, UK) and frozen on dry ice. Frozen sections were 
cut at 12 µm thickness, collected on Superfrost slides (Fisher Sci-
entific), dried and stored at -20 C. For immunohistochemistry, 
sections were fixed briefly in 4% PFA in TBS, rinsed in TBS and 
blocked for 1 hour in 1% BSA in TBS-Tween (0.5% Tween), before 
being incubated overnight with the following primary antibodies: 
NR5A1 (Invitrogen N1665/434200, 1:200), CYP11A1 (Sigma 
HPA016436, 1:20), NRK (Sigma HPA017238, 1:250), SOX9 
(Sigma HPA001758, 1:200), CITED1 (Abcam ab15036, 1:200), 
GRAMD1B (Sigma HPA008557, 1:200; Abnova PAB15705, 
1:200), RMDN2 (Sigma HPA034706, 1:200), FOXO4 (Cell Sig-
nalling 2499, 1:200), AMH (Abcam ab103233 1:200), INSL3 
(Sigma HPA028615, 1:1000), SCUBE1 (Abcam ab105358, 
1:50). The next morning, sections were washed in TBS-Tween 
and incubated for 1 hour with the relevant secondary antibodies: 
Alexa488 goat anti-mouse (Invitrogen A11001, 1:400) and Alexa555 
goat anti-rabbit (Invitrogen A21429, 1:400). Nuclei were counter-
stained with DAPI (10 µg/ml, Sigma). Slides were washed with 
TBS-Tween and mounted using ProLong Gold Antifade Mountant 
(Life Technologies). Images were collected on a Zeiss LSM 710 
confocal microscope (Carl Zeiss) and analysed using Zeiss Zen 
2009 and Image J (version 1.46r).
Results
Generation of an atlas of gene expression in human adrenal 
gland, testis and ovary
Human embryonic and fetal tissues of interest were obtained 
following ethical approval and with informed consent from the 
Human Developmental Biology Resource (HDBR, www.hdbr.
org). RNA was extracted and gene expression profiling performed 
using Affymetrix ST1.0 Gene arrays. A total of 53 different 
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Figure 2. Differential gene expression in adrenal gland, testis and ovary compared to controls. (a) Principal component analysis of the 
53 samples included in the study (17 adrenal, 20 testes, 10 ovary and 6 controls). The scatter plot shows the position of samples based on the 
two first principal components (PC1, PC2). (b) Venn diagram showing the overlap between differentially up-regulated genes in the adrenal, 
testis and ovary compared with control samples using either log2FC≥1 or log2FC≥2. (c) Selected examples of differentially up-regulated 
genes (log2FC≥2) involved in steroidogenesis (d) Selected transcription factors differentially expressed in each tissue (log2FC≥1). For all 
comparisons, P-value≤0.05.
organs between 42 days (6 weeks) and 70 days (10 weeks) post-
conception were included in the final analysis (Supplementary 
Table 1). This dataset consisted of 17 adrenal glands (46,XY), 
10 ovaries (46,XX), and 20 testes (46,XY), as well as 6 control 
samples (46,XY) from spine, brain, muscle, heart, kidney and 
liver. Adrenal and control samples with a 46,XY karyotype were 
intentionally chosen so that subtle effects of Y-chromosome genes 
on testis determination and sex development could be analysed. 
All relevant CEL files have been deposited in the ArrayExpress 
database (E-MTAB-5525) and the entire dataset of log2 normalised 
values is included in Dataset 1.
Initial comparisons of gene expression profiles in the different 
samples were undertaken using principal components analysis 
(PCA) and by generating correlation plots (heatmaps) and clus-
ter dendrograms (Figure 2a, Figure 3). Samples from each tissue 
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Figure 3. Cluster analysis for all 53 samples included in the study. (a) Correlation plot (heatmap) of gene expression. (b) Hierarchical 
cluster dendrogram using the agglomeration method ward.D2.
Page 7 of 42
Wellcome Open Research 2017, 2:25 Last updated: 08 NOV 2017
clearly clustered together, with more similarity between testis and 
ovary profiles than adrenal gland (Figure 2a, Figure 3).
Global gene expression patterns reveal known disease-
causing genes and identify novel tissue-specific factors
An analysis of global gene expression patterns was initially 
performed for the three tissues (adrenal, testis, ovary) compared 
to controls. Genes were identified that were up-regulated with a 
log2 fold change (FC) of ≥ 2 or ≥ 1 and adjusted P-value lower than 
0.05 (P≤ 0.05) (Dataset 2–Dataset 4).
An overview of the number of differentially up-regulated genes 
that are specific to each tissue, or overlapping, is shown in 
Figure 2b. As expected, there was greater overlap between testis 
and adrenal (due to shared steroidogenic pathways) and testis and 
ovary (due to their gonadal origin and presence of germ cells) 
than between adrenal and ovary, which are developmentally and 
functionally more distinct.
Analysis of factors known to be involved in steroidogenesis 
showed that shared components of the steroidogenic pathways 
overlapped in the adrenal and testis datasets (e.g. CYP11A1, 
HSD3B2, CYP17A1), whereas the gene responsible for conver-
sion of delta-4 steroids (e.g. androstenedione) into testosterone, 
HSD17B3, was the only testis-specific steroidogenic enzyme 
(Figure 2c). Adrenal-specific steroidogenic components included 
the enzymes needed to make aldosterone and cortisol from 
precursors (e.g. CYP11B1, CYP21A2) as well as adrenal-specific 
receptors involved in signalling pathways (e.g. MC2R [also known 
as the ACTH receptor], MRAP).
An analysis of known transcription factors (Figure 2d) revealed 
several key genes shared between the testis and ovary involved 
in gonad development (e.g., WT1, EMX2, LHX9, GATA4) or 
in germ cell maturation (e.g., POU5F1 [also known as OCT4] 
and NANOG) (Figure 2d). One key transcription factor shared 
between the adrenal and testis was the nuclear receptor NR0B1 
(also known as DAX-1), responsible for X-linked adrenal hypo-
plasia congenita with male infertility (Suntharalingham et al., 
2015). Another key nuclear receptor common to all three tissues 
was NR5A1 (also known as steroidogenic factor-1), responsible 
for adrenal insufficiency, testicular dysgenesis and primary ovar-
ian insufficiency (Achermann et al., 1999; Lourenço et al., 2009; 
Suntharalingham et al., 2015). Therefore, the dataset seemed vali-
dated based on known factors involved in development as well 
as in genetic conditions in humans.
Known and novel adrenal-specific genes
Initial analysis focused on genes up-regulated in the adrenal 
gland compared to controls (Figure 4a, Table 1 and Dataset 2). 
The most strongly differentially expressed adrenal genes were 
CYP17A1 (absolute FC 240.2), CYP11A1 (absolute FC 115.4), 
SULT2A1 (absolute FC 97.3), STAR (absolute FC 73.4), MC2R 
(the ACTH receptor) (absolute FC 62.3) and CYP11B1 (absolute 
FC 47.8) (Figure 4a–d and Table 1). These genes are known core 
components of adrenal steroidogenesis and most are associated 
with monogenic disorders in humans (Table 1). The most strongly 
differentially expressed transcription factors were FOXO4 (abso-
lute FC 10), NR0B1 (DAX-1) (absolute FC 9.5) and NR5A1 (SF-1) 
(absolute FC 7.8) (Figure 5a). Key novel genes or those that have 
not been extensively studied in the adrenal gland before include 
MGARP (also known as OSAP), MAP3K15, ASB4, NRK, and 
TDGF1 (Figure 4d). Expression of these genes was confirmed by 
qRTPCR and/or immunohistochemistry (Figure 4c, Figure 5b). 
Analysis of the heatmap for the top 50 differentially expressed 
genes revealed that several novel genes appear to be highly 
adrenal-specific (e.g., ASB4, NPR3, GRB14), whereas others are 
also expressed in the later testis samples, suggesting a potential 
novel role for these genes in steroidogenesis (see below) (Figure 4d).
SRY is the primary driver of human testis development
Studies in transgenic mice and humans with SRY deletions 
and translocations have suggested that SRY is the primary 
Y-chromosomal testis-determining gene in humans, but direct 
evidence is limited (Bashamboo et al., 2017; Hanley et al., 2000; 
Koopman et al., 2016). SRY is thought to be transiently up-regulated 
in the 46,XY bipotential gonad at around 42 dpc, leading to 
downstream expression of testis development pathways (Hanley 
et al., 2000). Analysis of SRY expression in early testis samples 
(CS18–CS19) compared to control tissues (all 46,XY) showed 
that SRY is the only significantly differentially-expressed protein 
coding  Y-chromosomal gene (absolute FC 2, P-value≤0.003) 
(Figure 6a and Dataset 5). Although changes are subtle, there was 
a clear transient expression of SRY that had occurred by the start of 
our dataset (around 45 dpc), with a reduction in intensity around 
CS23 (57 dpc) (Figure 6a, Figure 6b).
Other genes that are differentially expressed in the early testis 
compared to controls are shown in the heatmap in Figure 6c, 
Figure 7a and Figure 7b. These include the gene encoding 
renin (REN) as well as mesonephric factors such as NPHS2 and 
WT1. Pathway-enrichment analysis using ClueGO confirmed “sex 
differentiation” and “renal system development” as the two major 
up-regulated pathways in the dataset (Figure 7c).
Modelling dynamic changes in the testis downstream of 
SRY
Studies in mice have shown that SOX9 is a target of SRY, and 
disruption of SOX9 in humans results in testicular dysgenesis 
(Bashamboo et al., 2017; Bishop et al., 2000; Sekido & Lovell-
Badge, 2008). However, the dynamics of SOX9 expression in 
human testis development are still not well understood and it is 
not established whether SOX9 is the only potential SRY target 
(Hanley et al., 2000; Ostrer et al., 2007). Analysis of SOX9 
across the testis series revealed an approximate 2-fold increase in 
gene expression levels with a curvilinear pattern (Figure 8a).
In order to assess detailed patterns and changes in gene expression 
across the time series dataset, and to be able to group genes with 
similar dynamic expression patterns together, a phenomenological 
Page 8 of 42
Wellcome Open Research 2017, 2:25 Last updated: 08 NOV 2017
Figure 4. Differential expression of genes in the adrenal gland. (a) Correlation plot for log2 mean gene expression levels in the adrenal 
versus control samples (Pearson’s product-moment correlation test correlation coefficient=0.96, P-value≤ 2.2e-16). (b) Volcano plot analysis 
of differentially expressed genes in adrenal versus control samples. Genes with a log2FC≥2 (or log2FC≥-2) and P-value≤0.000005 are shown 
in orange. (c) Immunohistochemistry of NR5A1, CYP11A1 and NRK in the human adrenal gland (9 wpc). Nuclei are stained blue with DAPI, 
which also highlights the outer capsule. Scale bars, 100 µm. (d) Heatmap representing normalised gene expression values for the top 50 
differentially up-regulated adrenal genes compared to control samples across the whole sample dataset. Genes are ordered according to 
descending log2FC values. The intensity of gene expression is indicated by a colour scale: blue for lowest and red for highest expression 
levels. For all samples shown, P-value≤1e-10.
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Table 1. The top 20 differentially expressed adrenal genes and other selected genes associated with monogenic 
disorders in humans. Genes are ranked based on log2FC in the adrenal (n=17) compared to control samples (n=6). Further 
clinical information is available at Online Mendelian Inheritance in Man (OMIM).
Rank Gene log2FC
Fold 
change OMIM gene Clinical condition (monogenic)
1 CYP17A1 7.91 240.2 609300 Congenital adrenal hyperplasia (due to  
17 α-hydroxylase deficiency)
2 CYP11A1 6.85 115.4 118485 Congenital adrenal hyperplasia (due to CYP11A1/
P450scc deficiency)
3 SULT2A1 6.60 97.3 -
4 STAR 6.20 73.4 600617 Congenital lipoid adrenal hyperplasia; Familial 
glucocorticoid deficiency type 3
5 MC2R 5.96 62.3 607397 Familial glucocorticoid deficiency, type 1
6 CYP11B1 5.58 47.8 610613 Congenital adrenal hyperplasia (due to  
11 β-hydroxylase deficiency)
7 MGARP 5.21 37.1 -
8 GSTA1 5.15 35.5 -
9 MAP3K15 5.11 34.5 -
10 NPR3 4.62 24.6 -
11 ASB4 4.60 24.3 -
12 HPGD 4.46 22.0 601688 Cranioosteoarthropathy; Primary hypertrophic 
osteoarthropathy type 1
13 GNRHR 4.43 21.6 138850 Hypogonadotropic hypogonadism
14 C7 4.34 20.3 217070 C7 (complement) deficiency
15 SERPINA5 4.26 19.2 -
16 FDX1P1 4.26 19.1 -
17 SCARB1 4.15 17.8 601040 High-density lipoprotein elevation
18 NRK 4.09 17.1 -
19 CYP21A2 4.09 17.1 613815 Congenital adrenal hyperplasia (due to  
21-hydroxylase deficiency)
20 FDX1 4.03 16.3 -
21 PAPSS2 4.00 16.0 603005 Brachyolmia type 4 with mild epiphyseal and 
metaphyseal changes, adrenal hyperandrogenism
22 DHCR24 4.00 15.9 606418 Desmosterolosis
25 TDGF1 3.96 15.6 187395 Forebrain defects
36 INHA 3.67 12.8 147380 Adrenocortical carcinoma (paediatric)
43 APOA1 3.42 10.7 107680 Apoplipoprotein A-I deficiency
46 SAMD9 3.34 10.2 610456 MIRAGE syndrome (includes growth restriction, 
adrenal hypoplasia, testicular dysfunction)
49 NR0B1 
(DAX-1) 3.25 9.5 300473 X-linked adrenal hypoplasia congenita
50 HSD3B2 3.19 9.1 613890 Congenital adrenal hyperplasia (due to  
3 β-hydroxysteroid dehydrogenase deficiency type 2)
60 NR5A1 (SF-1) 2.96 7.8 184757 DSD (testicular dysgenesis/impaired testosterone 
synthesis) +/- adrenal insufficiency
72 LDLR 2.81 7.0 600694 Familial hypercholesterolaemia
77 AMHR2 2.73 6.7 600956 Persistent Müllerian duct syndrome, type 2
105 POR 2.53 5.8 124015 P450 oxidoreductase deficiency/Antley-Bixler 
syndrome
117 MRAP 2.43 5.4 615410 Familial glucocorticoid deficiency, type 2
142 NPC1 2.31 5.0 607623 Niemann-Pick disease type C1
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Figure 5. Analysis of differentially expressed adrenal genes. 
(a) Absolute fold change (FC) of the top 20 up-regulated transcription 
factors in the adrenal gland compared to control samples. Data 
are derived from the array dataset. (b) Confirmation of differential 
expression of several novel genes in the adrenal gland (9 wpc) by 
qRT-PCR. Pooled liver, brain and muscle were used as a control. 
GAPDH was used as a housekeeping gene.
in adult testis but also strongly in at least one other system (e.g., 
ANKRD18A, SLC52A3, KEL) (Human Protein Atlas). In addition, 
INHBB encodes the β-subunit of inhibin B, a well-established testis 
protein, which together with SOX9 provides validation for the data-
set (Valeri et al., 2013).
Identifying known and novel components of 
steroidogenesis
Using the “BALT” model across the time-series dataset, the 
expression of key known components of testis steroidogen-
esis showed marked upregulation around a fixed time point 
(“L”) between 54–57 dpc (LHCGR, STAR, CYP11A1, HSD3B2, 
CYP17A1, HSD17B3) (Figure 9a). Expression levels of all these 
enzymes showed a sigmoid-type pattern, suggesting that discrete 
biological events occur in this fixed window (Supplementary 
Table 3). The heatmap of normalised gene expression plots for 
these enzymes showed similar discrete changes between early 
testis (CS18 to CS22) and late testis (F1 to F3) for many known 
components involved in testosterone synthesis (Figure 9b). 
Principal components analysis also demonstrated segregation 
of samples into two distinct groups (Figure 10a). A subset of 
genes was seen to be up-regulated with age in a correlation plot 
(Figure 10b), and pathway-enrichment analysis strongly reflected 
processes involving “cholesterol”, “sterol” and “steroid” metabo-
lism or biosynthesis (Figure 10c). Therefore, CS23 (8 weeks) was 
a discrete point around which the onset of testicular steroidogen-
esis could be modelled, and samples either side of this time point 
were used for “pre-steroidogenesis” (“early”) versus “post- 
steroidogenesis” (“late”) comparisons. An overview of key genes 
in this dataset, many of which are associated with monogenic 
disorders in humans, is shown in Table 3.
In order to identify potential novel core components of 
steroidogenesis in the adrenal gland and testis, genes were identi-
fied that were both up-regulated in late testis samples compared to 
early ones (post-steroidogenesis versus pre-steroidogenesis, 
log2FC≥1), and up-regulated in adrenal samples versus con-
trols (adrenal versus controls, log2FC≥2) (Figure 11a). A total of 
45 overlapping genes were found, including all relevant known 
steroidogenic enzymes and 17 novel genes (Figure 11a–c, 
Table 4). Enrichment-pathway analysis showed upregulation 
of genes involved in “cholesterol transport and metabolism” as 
well as “steroid biosynthesis”, further validating the analysis 
(Figure 11d). The heatmap for these 45 genes confirmed highly 
selective expression in the fetal adrenal gland and in the fetal 
testis, but largely after CS23 (Figure 11c).
An overview of the proposed function of the 17 potentially 
novel factors is shown in Table 5. These genes include MGARP 
(also known as OSAP), which may be involved in mitochondrial 
trafficking, MAP3K15 (ASK3) involved in cell signalling of 
stress, and the imprinted gene DLK1 (PREF1) implicated in 
growth and differentiation (Guasti et al., 2013; Naguro et al., 2012; 
Zhou et al., 2011). Two genes that have not been studied previ-
ously are GRAMD1B and RMDN2 (FAM82A1). These genes are 
clearly expressed with the onset of steroidogenesis (Figure 11b,c) 
mathematical model was developed that allowed expression points 
of any gene to be described based on the basal gene expression 
value (“B”), the amplitude of the change (“A”), the localisation 
time of the maximum transition (“L”), and the rate of transition 
(“T”) (“BALT model”) (Figure 8b) (See methods for details).
Using this approach, several genes were found to have similar 
expression dynamics to SOX9 (Figure 8c, Figure 8d, Table 2 
and Supplementary Table 2). Analysis of the heatmap for these 
factors in the entire dataset showed that a subset of these genes 
had predominantly testis-specific upregulation (CITED1, ANK-
RD18A, G6PD, SLC52A3, KEL, ZNF280B, PRPS2, INHBB) 
(Figure 8d and Supplementary Figure 1). Immunohisto-
chemistry of human fetal testis showed strong expression of 
CITED1 in seminiferous cords in a similar pattern to SOX9 
(Figure 8e). Similar expression data are seen for CITED1 in 
the adult testis (CITED1 in the Human Protein Atlas). Adult 
expression data confirmed predominant testis expression 
of ZNF280B and PRPS2, whereas several other genes are expressed 
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Figure 6. SRY expression in early human testis and differential expression of other genes. (a) Heatmap showing normalised gene 
expression values for SRY across the whole sample dataset. (b) Scatter plot of normalised gene expression of SRY in testis samples between 
45 and 74 dpc. Loess method was used to fit a smooth curve between expression values. (c) Heatmap representing normalised gene 
expression values for the top 30 differentially up-regulated genes in early testis samples (CS18 and CS19 stages) (N=4) compared to control 
samples (N=6). Genes are ordered according to decreasing log2FC values. The intensity of gene expression is indicated by a colour scale: 
blue for lowest and red for highest expression levels. For all samples shown, P-value≤0.05.
and show strong expression in the cytoplasm of NR5A1 (SF-1) 
positive fetal Leydig cells and adrenal cells by immunohis-
tochemistry (Figure 12a–c, Supplementary Figure 2a,b and 
Supplementary Figure 3a). However, currently the true biological 
function of these genes remains unknown. The transcription 
factor FOXO4 showed expression in the nuclei of Leydig cells in 
the fetal testis (Figure 12d).
Identification of potential secreted proteins in the testis
The analysis of genes that showed progressive upregulation 
in the developing testis was extended to try to identify novel 
biomarkers. The protein structures encoded by genes that were 
up-regulated in late testis samples (F1 to F3; FC≥1, Dataset 6) 
were reviewed for characteristics of secreted proteins, such 
as the presence of a cleaved signal peptide. Using this approach, 
the three major testis biomarkers Anti-Müllerian Hormone 
(AMH/MIS), inhibin α-subunit (INHA) and insulin-like 3 
(INSL3) were identified (Figure 13a–c). Novel factors identified 
included EGFLAM, CARTPT, ADAMTS5, SCUBE1 and EPPIN 
(Figure 13a). Expression of SCUBE1 was shown in seminiferous 
cords in the developing testis (Figure 13d).
Ovarian development is not a passive process
Although ovary development was once thought to be a less bio-
logically active process, several studies in the mouse have 
shown changes in discrete sets of differentially expressed 
genes in the early ovary (Beverdam & Koopman, 2006; Jameson 
et al., 2012; Nef et al., 2005). However, it is unclear whether 
similar effects are also present during early human gonad 
development.
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Figure 7. Differentially expressed genes in the early testis compared to control samples. (a) Correlation plot for log2 mean gene 
expression levels in the early testis (CS18 to CS19) (N=4) versus control samples (N=6) (Pearson’s product-moment correlation test correlation 
coefficient=0.968, P-value≤ 2.2e-16). (b) Volcano plot for the differentially expressed genes in early testis versus control samples. Purple 
colour indicates genes with absolute log2FC≥1 and P-value≤ 0.05. (c) Pathway-enrichment analysis using ClueGO for differentially expressed 
up-regulated pathways in early testis compared to control samples (log2FC≥1, P-value≤0.005).
By studying up-regulated genes in the ovary and comparing them 
to control samples, (Dataset 4) and by studying up-regulated genes 
in the testis and comparing them to controls (Dataset 3), very simi-
lar numbers of gonad-specific differentially expressed genes were 
found (log2FC≥ 1, ovary 274 versus testis 280; log2FC≥2, ovary 
69 versus testis 57) (Figure 14a). As expected, there was substan-
tial overlap in genes that were co-expressed in both the ovary and 
the testis (log2FC≥1, 463; log2FC≥2, 68). Although the number of 
strongly up-regulated genes was somewhat higher in the testis com-
pared to the ovary when observed in a volcano plot (Figure 14b and 
Dataset 7), in part due to Y chromosomal genes, a similar scatter of 
up- and down-regulated genes was seen for the ovary versus control 
as for the testis versus control, again reinforcing the concept of the 
developing ovary having discrete genetic activity (Figure 14c).
Analysis of the top 20 up-regulated genes in the ovary compared 
to control data is shown in the heatmap in Figure 14d. Many of 
these genes were also expressed to some extent in the testis, and 
may represent factors involved in pluripotency and germ cell 
development such as HIST1H2BA, NANOG and POU5F1 (also 
known as OCT4). Expression of several genes appeared to increase 
in the ovary across the time course (CS18 to F2) and to decrease 
in the testis, such as OR10G9, GABRG1, OR4D5, NPNT, CNT-
NAP4 and NPY (Figure 14d). These genes could potentially encode 
novel components of an ovary-specification program. However, 
pathway-enrichment analysis of the 274 genes differentially up-
regulated in the ovary compared to controls (log2FC≥1, P<0.05) 
resulted in very few biological processes other than “germ 
cell development” and “type 1 interferon signalling pathway” 
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Figure 8. Identification of potential genes downstream of SRY using the BALT model. (a) Scatter plot showing curvilinear upregulation 
of SOX9 during testis development (45 to 74 dpc). Loess method was used for fitting a smooth curve between variables. (b) Equation used 
in the BALT mathematical model (see methods for details). (c) Scatter plots showing changes in gene expression patterns for CITED1, 
ANKRD18A, PRPS2 and ZNF280B in the developing testis (45 to 74 dpc). Loess method was used for fitting a smooth curve between variables. 
(d) Heatmap representing normalised gene expression values for genes showing similar expression patterns to SOX9, based on the BALT 
mathematical model. The intensity of gene expression is indicated by a colour scale: blue for lowest and red for highest expression levels. For 
all samples shown, P-value≤0.005. (e) Immunohistochemistry for NR5A1 (SF-1, staining Leydig cells), SOX9, and CITED1 in the human fetal 
testis (11 wpc). Nuclei are counterstained blue with DAPI. Scale bars, 100 µm.
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Table 2. Potential biological functions of genes up-regulated during early testis development. Monogenic 
disorders associated with these factors are shown in italics. Potential function has been summarised from data in 
the GeneCards database.
Gene Protein Potential function
ASPN Asporin Leucine-rich repeat (LRR) protein associated with the 
cartilage matrix
GSTA1 Glutathione- S-transferase, alpha-1 Enzyme involved in detoxification of cellular compounds 
by conjugation with reduced glutathione
CITED1 CBP/p300-interacting transactivator 
with Glu/Asp-rich-C-terminal domain
Transcriptional co-regulator
ANKRD18A Ankyrin repeat domain-containing 
protein 18A
Unknown
MOCOS Molybdenum cofactor sulfurase Enzyme involved in sulphuration of the molybdenum 
cofactor of xanthine dehydrogenase and aldehyde 
oxidase
HIST1H2AA Histone gene cluster 1, H2A histone 
family, member A
Replication-dependent histone
MAPK4 Mitogen-activated protein kinase 4 Regulator of cell signalling
NOSTRIN Nitric oxide synthase trafficker Protein that binds endothelial nitric oxide synthase (eNOS) 
and triggers translocation of ENOS from the plasma 
membrane to sub-cellular structures
G6PD Glucose-6-phosphate 
dehydrogenase
Enzyme involved in generation of NADPH in the hexose 
monophosphate pathway (associated with G6PD 
deficiency)
RASSF2 RAS association domain family 
protein 2
Protein that interacts with RAS proteins in cell growth and 
mitogenesis
SLC52A3 Solute carrier family 52, member 3 Transmembrane protein that mediates cellular uptake 
of riboflavin (associated with Brown-Vialetto-van Laere 
syndrome type 1)
KEL Kell blood group 
metalloendopeptidase
Metalloendopeptidase that generates active endothelin-3 
from big endothelin-3
ZNF280B Zinc finger protein 280B Transcription factor that upregulates expression of MDM2 
and negatively regulates p53
PRPS2 Phosphoribosylpyrophosphate 
synthetase 2
Enzyme involved in regulation of nucleotide production 
pathways
SOX9 SRY-box 9 Transcription factor involved in the regulation of testis 
development
INHBB Inhibin beta B Growth and differentiation factor involved in reproduction 
and development
(Figure 15a). In contrast, pathway-enrichment analysis for the 280 
genes up-regulated in the testis samples versus controls (log2FC≥1, 
P<0.05) revealed many more detailed networks, with enrich-
ment in terms such as “androgen” and “reproductive” processes 
(Figure 15b). Taken together, these data suggest that current 
knowledge of the genetic events in the early stages of human ovary 
development is still very limited.
Discussion
Adrenal development and gonad development are two of the 
most fundamental biological processes. However, current knowl-
edge about the genetic mechanisms underlying these events is 
derived largely from studies in mice (Beverdam & Koopman, 
2006; Inoue et al., 2016; Jameson et al., 2012; McClelland et al., 
2015; McClelland & Yao, 2017; McDowell et al., 2012; Nef et al., 
2005; Xing et al., 2015) and few data are currently available from 
humans (Fowler et al., 2009; Gerrard et al., 2016; Houmard 
et al., 2009; O’Shaughnessy et al., 2007), especially during the 
first trimester or across all three tissues. Of the published data, the 
recent study from Gerrard et al. provides the most detailed 
insight into early human adrenal and testis expressed genes cur-
rently available, but this work included just two samples from 
pooled RNA between CS18 and CS22 (Gerrard et al., 2016). Given 
the potential biological differences between species, as well as a 
lack of detailed time course data for all three tissues, our aim was 
to generate a detailed “Atlas” of genomic events across a critical 
period in human embryonic and fetal development (6 to 10 wpc).
Initial analysis focused on global gene expression patterns in 
the adrenal, testis and ovary compared to control tissues. Control 
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Figure 9. Determination of genes up-regulated with the onset of fetal testicular steroidogenesis. (a) Scatter plots showing changes in 
gene expression patterns for known testicular steroidogenic genes, LHCGR, STAR, CYP11A1, HSD3B2, CYP17A1 and HSD17B3. The plot 
shows normalised gene expression values for testis samples between approximately 46 and 74 dpc. Loess method was used for fitting a 
smooth curve between variables. (b) Heatmap representing normalised gene expression values for the top 30 differentially up-regulated 
genes when comparing late (F1 to F3) (N=8) and early (CS18 to CS22) (N=9) testis samples. The intensity of gene expression is indicated 
by a colour scale: blue for lowest and red for highest expression levels. For all samples shown, P-value≤1e-4. Genes are ordered according 
to descending log2FC values.
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Figure 10. Differentially expressed genes in early compared to late testis samples. (a) Principal component analysis of early (N=9) 
compared to late (N=8) testis samples. The scatter plot shows samples plotted on the two first principal components (PC1, PC2). 
(b) Correlation plot for log2 mean gene expression levels in the early testis (CS18 to CS22) versus late testis (F1 to F3) samples (Pearson’s 
product-moment correlation test correlation coefficient=0.992, P-value< 2.2e-16). (c) Pathway-enrichment analysis using ClueGO for 
differentially up-regulated genes in early testis compared to late testis samples (log2FC≥1, P-value≤0.01).
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Table 3. The top 20 differentially expressed genes after the onset of testicular steroidogenesis (“late testis” vs 
“early testis”), with any associated clinical conditions in humans. Several other high-ranking genes associated 
with monogenic disorders are also shown. Genes are ranked based on log2FC in the late testis (n=8) compared to 
early testis (n=9). Further clinical information is available at Online Mendelian Inheritance in Man (OMIM).
Rank Gene log2FC
Fold 
change
OMIM 
gene Clinical condition (monogenic)
1 CYP17A1 5.27 38.5 609300 Congenital adrenal hyperplasia (due to 17  
α-hydroxylase deficiency)
2 LHCGR 3.47 11.1 152790 Leydig cell hypoplasia
3 INSL3 3.13 8.8 146738 Cryptorchidism
4 CYP11A1 3.08 8.5 118485 Congenital adrenal hyperplasia (due to CYP11A1/
P450scc deficiency)
5 CALB2 2.86 7.3
6 SCARB1 2.83 7.1 601040 High-density lipoprotein elevation
7 STAR 2.54 5.8 600617 Congenital lipoid adrenal hyperplasia; Familial 
glucocorticoid deficiency type 3
8 DHCR24 2.22 4.6 606418 Desmosterolosis
9 ABCA10 2.21 4.6
10 MGARP 2.16 4.5
11 MSMO1 2.12 4.3 607545 Microcephaly, congenital cataract and psoriasiform 
dermatitis
12 RNU6-1160P 2.11 4.3
13 GRAMD1B 2.04 4.1
14 HSD17B6 2.03 4.1
15 EGFLAM 2.02 4.1
16 ABCA8 2.02 4.0
17 IDI1 2.01 4.0
18 LDLR 1.95 3.9 600694 Familial hypercholesterolaemia
19 LUM 1.95 3.9
20 SPARCL1 1.94 3.8
22 HSD3B2 1.92 3.8 613890 Congenital adrenal hyperplasia (due to  
3 β-hydroxsteroid dehydrogenase deficiency type 2)
23 DHCR7 1.92 3.8 602858 Smith-Lemli-Opitz syndrome
24 C7 1.87 3.7 217070 C7 (complement) deficiency
25 HSD17B3 1.87 3.7 605573 17 β-hydroxysteroid dehydrogenase deficiency  
type 3
28 HPGD 1.84 3.6 601688 Cranioosteoarthropathy; Primary hypertrophic 
osteoarthropathy type 1
29 PAPSS2 1.83 3.5 603005 Brachyolmia type 4 with mild epiphyseal and 
metaphyseal changes, adrenal hyperandrogenism
41 FDPS 1.61 3.0 134629 Porokeratosis type 9
42 MVD 1.59 3.0 603236 Porokeratosis type 7
49 NPC1 1.55 2.9 607623 Niemann-Pick disease type C1
68 INHA 1.40 2.6 147380 Adrenocortical carcinoma (paediatric)
100 AMH 1.18 2.3 600956 Persistent Müllerian duct syndrome, type 1
119 POR 1.07 2.1 124015 P450 oxidoreductase deficiency, Antley-Bixler 
syndrome
Page 18 of 42
Wellcome Open Research 2017, 2:25 Last updated: 08 NOV 2017
Figure 11. Identification of novel steroidogenesis genes. (a) Venn diagram displaying the overlap for up-regulated genes between 
adrenal and control samples (log2FC≥2) with late versus early testis samples (log2FC≥1). A subset of genes found in the intersection are 
displayed, which are not yet established components of steroidogenesis. In all cases, P-value≤0.05. (b) Scatter plots showing changes in 
gene expression patterns for four novel factors, GRAMD1B, RMDN2, MAP3K15, and FOXO4. The plot shows normalised gene expression 
values for testis samples between approximately 46 and 74 dpc. Loess method was used for fitting a smooth curve between variables. 
(c) Heatmap representing normalised gene expression values for the 45 genes identified in the intersection between adrenal versus control 
and late testis versus early testis. The intensity of gene expression is indicated by a colour scale: blue for lowest and red for highest 
expression levels. Row-based unsupervised hierarchical clustering was performed. (d) Pathway-enrichment analysis using ClueGO for the 
45 genes identified in the intersection shown in (a).
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Table 4. Known and potentially novel genes identified as components of 
steroidogenesis in humans. These 45 genes were determined from the overlap 
between genes differentially expressed in the adrenal gland vs. control (log2FC≥2) 
and in the testis vs. control (log2FC≥1).
Steroidogenesis
CYP17A1, CYP11A1, STAR, FDX1P1, FDX1, PAPSS2, HSD3B2, POR
Cholesterol metabolism & oxidative stress
SERPINA5, SCARB1, DHCR24, APOA1, APOC1, MSMO1, AS3MT, LDLR, DHCR7, 
ACSS1, NPC1, PDK4, ABCA5, IDI1, GPD1L, HMGCR
Oxidative stress
GSTA1, MGST1, SLC8B1, GSTA3
Novel
MGARP (OSAP), MAP3K15, HPGD, C7, MT2A, DLK1 (PREF1), INHA, FOXO4, 
GRAMD1B, RMDN2, SLC46A3, SLC16A9, COL15A1, AVPI1, FRRS1, VCAM1, 
FLJ38894
Table 5. Overview of potentially novel genes identified in human steroidogenesis. Potential function has been summarized 
from data in the GeneCards database, www.genecards.org.
Rank Gene Protein OMIM gene Potential function
1 MGARP  (OSAP)
Mitochondria localized glutamic 
acid rich protein -
Possible mitochondrial integrity and trafficking of 
mitochondria along microtubules
2 MAP3K15  (ASK3)
Mitogen-activated protein kinase 
kinase kinase 15 300820 Cell signalling of stress and apoptosis
3 HPGD 15-hydroxyprostaglandin dehydrogenase 601688
Metabolism and degradation of prostaglandins and 
NAD-dependent dehydrogenation
4 C7 Complement component 7 217070 Cytolytic phase of complement activation forming part of the membrane attack complex
5 MT2A Metallothionein 2A 156360 Possible regulation of oxidative stress and binding to metal ions
6 DLK1  (PREF1, FA1)
Delta-like non-canonical notch 
ligand 1 176290
Imprinted (paternally expressed) regulator of cell 
growth and differentiation 
7 INHA Inhibin alpha 147380
Alpha subunit of TGF-beta glycoprotein hormone 
involved in regulation of hormone secretion, cell 
growth and apoptosis. Variants implicated in 
paediatric adrenal cancer. 
8 FOXO4 Forkhead box O4 3000033 Transcription factor involved in oxidative stress, growth and differentiation, and leukaemia
9 GRAMD1B GRAM domain containing 1B (612559) Locus has susceptibility to chronic lymphocytic leukaemia
10 RMDN2  (FAM82A1)
Regulator of microtubule 
dynamics 2 611872 Microtubule association during cell division
11 SLC46A3 Solute carrier family 46,  member 3 616764 Membrane transport of small molecules
12 SLC16A9 Solute carrier family 16,  member 9 614242
Monocarboxylic acid transporter across plasma 
membranes
13 COL15A1 Collagen type XV, alpha-1 120325 Structural component of muscle and vessels, possible precursor of restin (antiangiogenic)
14 AVPI1 Arginine vasopressin induced 1 - May be involved in MAP kinase activation and cell cycling
15 FRRS1 Ferric chelate reductase 1 611578 Reduces ferric to ferrous iron before its transport from the endosome to cytoplasm
16 VCAM1 Vascular cell adhesion  molecule 1 192225
Glycoprotein expressed in endothelial cells, interacts 
with integrins on leukocytes to mediate adhesion and 
signal transduction
17 FLJ38894 - -
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Figure 12. Validation of novel steroidogenic genes. (a) Immunohistochemistry for GRAMD1B in human fetal testis at 9 wpc. NR5A1 
(SF-1) was used to highlight Leydig cells (green). DAPI was used to counterstain nuclei (blue) and to highlight the outer capsule. Scale bars, 
50 µm (top panels) and 20 µm (bottom panels). (b) Immunohistochemistry of RMDN2 performed as above. Scale bars, 50 µm (top panels) 
and 20 µm (bottom panels). (c) Immunohistochemistry of GRAMD1B and RMDN2 in the fetal adrenal gland at 9 wpc. NR5A1 (SF-1) was used 
to highlight the definitive zone and fetal zone cells (green). DAPI was used to counterstain nuclei (blue) and to highlight the outer capsule. 
Scale bars, 100 µm. (d) Immunohistochemistry for FOXO4 in human fetal testis at 11 wpc. NR5A1 (SF-1) was used to highlight Leydig cells 
(green). DAP-I was used to counterstain nuclei (blue). Scale bar, 100 µm (top panels) and 20 µm (bottom panels).
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Figure 13. Identification of potential testis-secreted proteins. (a) Heatmap representing normalised gene expression values for potential 
secreted proteins. The intensity of gene expression is indicated by a colour scale: blue for lowest and red for highest expression levels. 
(b) Immunohistochemistry for AMH (MIS) in human fetal testis at 9 wpc. NR5A1 (SF-1) was used to highlight Leydig cells (green). DAPI 
was used to counterstain nuclei (blue) and to highlight the outer capsule. Scale bars, 100 µm (top panels) and 20 µm (bottom panels) 
(c) Immunohistochemistry for INSL3 in human fetal testis at 9 wpc. NR5A1 (SF-1) was used to highlight Leydig cells (green). DAPI was used 
to counterstain nuclei (blue). Scale bar, 50 µm (d) Immunohistochemistry for SCUBE1 in human fetal testis at 9 wpc. NR5A1 (SF-1) was used 
to highlight Leydig cells (green). DAPI was used to counterstain nuclei (blue). Scale bars, 100 µm (top panels) and 20 µm (bottom panels).
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Figure 14. Ovary development dynamics. (a) Venn diagram displaying the overlap for up-regulated genes between ovary and control 
versus testis and control samples using log2FC≥1 (upper panel) and log2FC≥2 (lower panel) cut-offs. P-value≤0.05. (b) Volcano plot analysis 
of differentially expressed genes in ovary versus testis samples. Genes with an absolute log2FC≥1 and P-value≤0.05 are shown in pink. 
(c) Volcano plot analysis of differentially expressed genes in the ovary versus control samples (left panel) and testis versus control samples 
(right panel). Genes with an absolute log2FC≥1 and P-value≤0.05 are shown in pink and purple respectively. (d) Heatmap representing 
normalised gene expression values for the top 20 differentially expressed genes found only in the ovary versus control samples, using 
a log2FC≥2 cut-off. The intensity of gene expression is indicated by a colour scale: blue for lowest and red for highest expression levels. 
P-value≤1e-5. Genes are ordered according to decreasing log2FC values.
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Figure 15. Pathway enrichment analysis of ovary-specific genes. (a) Pathway-enrichment analysis using ClueGO for differentially up-
regulated genes in the ovary compared to control, with testis up-regulated genes excluded (log2FC≥1, P-value≤0.05). (b) Pathway-enrichment 
analysis using ClueGO for differentially up-regulated genes in the testis compared to control, with ovary up-regulated genes excluded 
(log2FC≥1, P-value≤0.05).
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samples were chosen to represent a range of developmental tissues 
(neuroectoderm, mesoderm, endoderm) across the study period. 
Approximately 0.5–1% of all genes were differentially expressed 
in each tissue at log2FC≥2 (absolute fold change 4) and 3–5% of 
all genes at log2FC≥1 (absolute fold change 2). The strong overlap 
between the adrenal and testis partly reflected shared components 
of steroidogenesis, whereas the overlap between testis and ovary 
reflected the shared origins of these tissues as well as the presence 
of germ cells.
Initial validation of our dataset came from known genes involved 
in distinct biological processes or monogenic disorders in humans. 
For example, two of the most strongly expressed transcription 
factors were the nuclear receptors NR0B1 (DAX-1), which was 
found in the adrenal and testis, and NR5A1 (SF-1), which was 
found in all three tissues. Pathogenic variants in NR0B1 cause 
X-linked adrenal hypoplasia and impaired spermatogenesis in 
males (Suntharalingham et al., 2015), whereas pathogenic vari-
ants in NR5A1 are associated with adrenal insufficiency, testicu-
lar dysfunction and primary ovarian insufficiency (Achermann 
et al., 1999; Lourenço et al., 2009; McElreavey & Achermann, 
2017; Suntharalingham et al., 2015). These findings, together 
with the identification and distribution of steroidogenic compo-
nents and the detection of known gonadal regulators (e.g. EMX2, 
LHX9, TCF21, WT1, GATA4) and germ cell pluripotency factors 
(e.g POU5F1, NANOG) provided strong validation for our dataset 
(Svingen & Koopman, 2013).
Analysis of genes that were differentially expressed in the 
adrenal gland provided further support for our experimental 
approach. The six genes most strongly expressed all represent 
major core components of adrenal steroidogenesis (CYP17A1, 
CYP11A1, SULT2A1, STAR, MC2R, CYP11B1) (Miller & Auchus, 
2011). All have associations with human adrenal disorders 
except for sulfotransferase 2A1, which is involved in sulpha-
tion of dehydroepiandrosterone (DHEA) to dehydroepiandroster-
one sulphate (DHEAS), the main steroid synthesised by the fetal 
adrenal zone. Novel factors identified in the adrenal gland include 
adrenal-specific factors such as ASB4 and NPR3, and two kinases 
(MAP3K15, NRK) that are also expressed in the testis. FOXO4 and 
TBX3 emerged as novel transcription factors that have not previ-
ously been implicated in adrenal development. Of note, several 
genes associated with adrenal insufficiency in humans were not 
differentially expressed during early development; namely NNT, 
TXNRD2, AAAS, MCM4 and SGPL1. Most of these factors have 
ubiquitous expression and may have a pathogenic effect through 
oxidative stress pathways or through the accumulation of toxic 
metabolites. These conditions may be precipitated by postnatal 
stress and affected children very rarely present with adrenal insuf-
ficiency in early infancy, unlike other conditions associated with 
differentially expressed genes where children often present in the 
neonatal period (e.g. NR0B1, NR5A1, SAMD9, CDKN1C, MRAP, 
MC2R, STAR, CYP11A1, HSD3B2, CYP17A1, POR, CYP21A2, 
CYP11B1) (Guran et al., 2016).
The role of SRY as the primary testis-determining gene has been 
known for 25 years, following transgenic mouse studies as well 
as the discovery of duplication of SRY in individuals with 46,XX 
testicular disorders of sex development (DSD) or disruption of 
SRY in 46,XY testicular dysgenesis (Bashamboo et al., 2017; 
Koopman et al., 2016; Svingen & Koopman, 2013). SRY is believed 
to undergo a transient wave of expression in the developing testis 
that regulates transcription of downstream factors such as SOX9 
and initiates testis development pathways (Hiramatsu et al., 2009). 
Although in situ hybridization studies of SRY in early human 
testis have been reported, suggesting onset of SRY expression at 
approximately 42 dpc, data regarding SRY expression in humans 
are still very limited (Hanley et al., 2000). SRY is already up- 
regulated at the start of our study (45 dpc) and falls with the onset 
of steroidogenesis around 56dpc. By comparing early testis samples 
(CS18–CS22) with 46,XY controls, SRY was the only protein cod-
ing Y-chromosome gene detected. Although it is widely assumed 
that SRY is the only Y-chromosomal testis-determining factor, this 
provides the first direct evidence in humans that this is the case.
Other genes up-regulated in the early testis show an overlap 
with mesonephric development and factors involved in nephrotic 
syndrome (e.g., NPHS2, WT1). Of note, the highest differen-
tially expressed gene encodes renin (REN), which supports data 
from previous studies of mouse testis development (Beverdam & 
Koopman, 2006; Bouma et al., 2007; Inoue et al., 2016; Nef 
et al., 2005). Renin is a hormone typically secreted from the jux-
taglomerular apparatus in the kidney that regulates angiotensin 
and aldosterone, thereby modulating renal sodium reabsorption 
and arterial blood pressure. Its role in the testis is unclear, as is 
its expression in extra-adrenal tissue. Furthermore, it has been 
proposed that SRY-dependent expression of renin-angiotensin 
system genes, including REN itself, is a major factor responsible 
for differences in blood pressure between men and women (Araujo 
et al., 2015; Prokop et al., 2012).
It is well-established that SOX9 is a target of SRY in testis deter-
mination, and SOX9 expression rises in the early human testis 
following expression of SRY (Hanley et al., 2000; Ostrer et al., 
2007; Sekido & Lovell-Badge, 2008). Although data from mice and 
humans suggest that SOX9 is in itself sufficient to trigger down-
stream testis pathways (Bishop et al., 2000; Kim et al., 2015) it is 
unclear if other SRY targets exist, or what direct targets of SOX9 
might be. Attempts have been made to investigate this using ChIP-
Chip in mice, but this approach is challenging given the amount of 
fetal tissue needed at the correct stage of development (Bhandari 
et al., 2012; Li et al., 2014).
An alternative approach is to study the pattern of SOX9 expres-
sion across a time-series, and to identify other genes with similar 
expression profiles. Rather than using a correlative approach, we 
developed a mathematical model that could be used to capture sub-
tle changes in our dataset more quantitatively. Using this approach, 
coupled with subsequent review of gene expression in different 
fetal and adult tissues, we have identified a small group of genes 
that are up-regulated with SOX9 in the testis (e.g., CITED1, 
ZNF280B, PRPS2).
Of these, CITED1 (encoding Cbp/p300 interacting transactivator 
with Glu/Asp rich carboxy-terminal domain 1) is of greatest inter-
est, as it is a transcriptional co-regulator, and strongly expressed 
in the adult testis, epididymis and pituitary gland. Cited1 knock-
out mice have growth restriction, late placental insufficiency and 
abnormalities in nephron patterning and pubertal mammary duc-
tal morphogenesis (Howlin et al., 2006; Novitskaya et al., 2011; 
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Plisov, 2005; Rodriguez et al., 2004). Although Cited1 was identi-
fied as a target of Sry in one mouse ChIP-CHIP study (Li et al., 
2014), little is known about Cited1 in mouse testis. In contrast, the 
related protein Cited2 influences adrenal and gonad development 
in the mouse, potentially through the regulation of Sf1 as well as 
of Sry itself (Buaas et al., 2009; Combes et al., 2010). CITED2 
is ubiquitously expressed in humans and does not show differen-
tial expression in our datasets, and pathogenic variants in CITED2 
have not been found in patients with adrenal and adrenogonadal 
disorders, suggesting that CITED1 might be a more important co-
regulator in humans (Ferraz-de-Souza et al., 2009). Amongst the 
other key genes identified, ZNF280B has been proposed to encode a 
negative regulator of p53 in prostate cancer cells (Gao et al., 2013), 
whereas PRPS2 encodes a testis specific phosphoribosylpyro-
phosphate synthetase that may function as an anti-apoptotic factor 
(Lei et al., 2015; Taira et al., 1990).
The advantage of having multiple serial samples for the testis is 
that the BALT model could be used to accurately pinpoint the onset 
of steroidogenesis. Using this approach a distinct sigmoid-shaped 
upregulation of all the known genes involved in testicular steroido-
genesis was seen between 54 and 57 dpc, with marked increases in 
fold-change. This discrete change in activity allowed us to divide 
the datasets into “pre-steroidogenic” and “post-steroidogenic” 
stages.
In order to identify novel components involved in steroidogenesis, 
genes were identified that were up-regulated in the testis post- 
steroidogenesis compared to pre-steroidogenesis, and also up- 
regulated in the adrenal gland compared to control samples. 
A total of 45 genes were identified, including all known core 
components of steroidogenesis and many factors involved in 
cholesterol biosynthesis and oxidative stress.
The 17 “novel” genes identified included MGARP (also known 
as OSAP), DLK1 (PREF1), and MAP3K15 (ASK3). MGARP has 
been implicated in mitochondrial trafficking and steroidogenesis 
(Jia et al., 2014; Jin et al., 2012; Zhou et al., 2011), but may 
also be a key target of OCT4 during reprogramming to pluripo-
tency (Tiemann et al., 2014). DLK1 is an imprinted gene that is 
involved in inhibiting adipocyte differentiation, which has previ-
ously been shown to be expressed in the outer undifferentiated zone 
of the male rat adrenal gland and signals to the adrenal capsule 
to regulate zonation (Guasti et al., 2013). MAP3K15 seems to be 
a novel kinase linked to steroidogenesis, which has very recently 
been shown to be differentially expressed in the adult adrenal 
gland (Bergman et al., 2017). Of note, the Map3k15/Ask3 knock-
out mouse is hypertensive and studies have linked this kinase to 
the response to osmotic stress and blood pressure regulation in 
the mouse kidney, through interactions with WNK1 or WNK4 
(Maruyama et al., 2016; Naguro et al., 2012). In our dataset, 
MAP3K15 was predominantly expressed in steroidogenic tissue, 
and not in the kidney. Similar findings are seen in RNA expres-
sion data for MAP3K15 in the Human Protein Atlas. Taken together, 
these findings suggest that adrenal effects of MAP3K15 may be an 
important area to focus future research on.
Other potential novel components of steroidogenesis with un-
known function include FOXO4, GRAMD1B and RMDN2 
(FAM82A1). FOXO transcription factors play important roles in 
development, cancer and metabolic homeostasis (Coomans de 
Brachène & Demoulin, 2016). FOXO4 has been implicated as a 
negative regulator of cell proliferation in several tumours, but a link 
to steroidogenesis has not previously been established (Li et al., 
2016). GRAMD1B has been shown to be enriched in mouse fetal 
Leydig cells following CRHR1 agonist stimulation (McDowell 
et al., 2012), and has been identified in other expression studies 
of mouse fetal Leydig cells (Inoue et al., 2016; McClelland & 
Yao, 2017). We have shown by immunohistochemistry that there 
is clear upregulation of GRAMD1B in the cytoplasm of NR5A1-
positive steroidogenic cells with the onset of steroidogenesis in 
humans. Similar upregulation of expression of RMDN2, a puta-
tive microtubule regulator, was also seen in these cells. However, 
the exact functional role of both GRAMD1B and RMDN2 in 
steroidogenesis is currently unknown.
In addition to steroidogenesis, the fetal testis has important 
biological roles through the secretion of proteins or hormones that 
regulate Müllerian regression (e.g., AMH), endocrine feedback 
(e.g., inhibin B) and testis descent (e.g. INSL3) (Valeri et al., 2013). 
These circulating proteins are also proving to be important biomar-
kers of testis integrity and function postnatally. Using a strat-
egy to identify genes encoding secreted proteins, all three major 
factors were identified, namely AMH, inhibin (α-subunit) and 
INSL3. Potential novel secreted proteins include EPPIN, which has 
been extensively studied as a novel approach to male contracep-
tion (O’Rand et al., 2016), and SCUBE1, a secreted cell surface 
glycoprotein belonging to the EGF superfamily. SCUBE1 was 
first identified from vascular endothelial cells and is released by 
activated platelets. Plasma levels of SCUBE1 have been meas-
ured as a potential biomarker in several conditions, such as gastric 
cancer, hypertension, ischaemic heart disease, and stroke 
(Özkan et al., 2013). Higher levels of SCUBE1 have been reported 
in adult males compared to females in some, but not all studies, 
although few control data exist (Ulusoy et al., 2012). An acute 
elevation in SCUBE1 has been demonstrated in experimental 
models of rat testis torsion, but it is unclear whether testicular 
SCUBE1 contributes significantly to circulating levels of SCUBE1 
in humans (Turedi et al., 2015).
Although ovary development was originally viewed as a rela-
tively passive process compared to testis development, studies in 
mice have shown that a similar number of differentially expressed 
genes are up-regulated in both organs during early development 
(Beverdam & Koopman, 2006; Bouma et al., 2007; Nef et al., 
2005). Our data show that this is true in human gonad develop-
ment too, with 274 and 280 genes differentially expressed in the 
ovary and testis, respectively, at log2FC>1, and 69 and 57 genes 
at log2FC>2. However, pathway-enrichment analysis of the 
tissue-specific genes revealed virtually no annotated pathways in 
the ovary, whereas tissue-specific pathways were more abundant 
in the testis. As expected, amongst the differentially-expressed 
ovary factors are several key genes involved in germ cell develop-
ment, e.g. NANOG, POU5F1, TFAP2C, ZFP42 (REX1). In addi-
tion, several genes involved in neurotransmission were higher in the 
developing ovary but were attenuated in the developing testis 
(OR10G9, GABRG1, OR4D5, NPNT, CNTNAP4 and NPY). These 
include two olfactory receptors of unknown function, a GABA 
receptor isoform subunit, neuropeptide Y and contactin associated 
protein like 4 (CNTNAP4), which has recently been implicated 
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in GABAergic synaptic transmission (Karayannis et al., 2014). 
Clearly, our understanding of very early human ovary development 
is still limited.
Although we feel this is an important study in human development, 
there are several limitations. Firstly, whole tissue samples were 
used for RNA extraction and RNA analysis. Using this approach 
transcriptomic signals from small populations of cells might be 
relatively attenuated. For example, the interstitial/Leydig cell 
population in the testis is only a relatively small population of the 
total number of cells. We have addressed this by studying relative 
changes in gene expression over time, which is independent of the 
total signal strength, and confirming key findings by immunohisto-
chemistry, although the proportion of cell populations many also 
change with time. Future studies of single cell transcriptomics will 
be able to address this in more detail. Secondly, these studies use 
microarray analysis rather than RNA-Seq. Microarray analyses are 
restricted by the specificity and number of probes and the arrays 
used in this study did not address differently spliced isoforms. 
Future studies using RNA-Seq might address both these points.
Conclusion
We have developed an important dataset describing the genomic 
landscape across three different tissues and spanning critical stages 
in human embryonic and fetal development. We have identified 
several important elements previously determined from studies in 
mice (e.g. Renin in testis), but also several novel aspects that may 
be specific to humans (e.g. CITED1 rather than CITED2 in early 
testis). By studying time-series changes and differential expression 
patterns, we have discovered novel components of these impor-
tant biological processes and interesting new pathways for further 
investigation. The dataset is highly validated based on known 
human disorders of adrenal and gonad function and will provide 
important insight to assign likely biological significance to new 
genes identified in whole exome and whole genome studies of 
patients with undiagnosed conditions. Finally, from the limited 
number of examples discussed above, novel insights from our 
genomic atlas could fuel many aspects of translational research, 
including biological sex-differences in humans, vulnerability to early 
life insults and programming, blood pressure regulation and stem 
cell/germ cell development.
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Research manuscript entitled   by del Valle “A genomic atlas of human adrenal and gonad development” et
 is an ambitious research effort and it addresses many puzzling questions concerning embryonic andal.
early fetal gonad and adrenal gland development in human. The authors need to be thanked for taking up
such a challenge and congratulated for being able to create a nicely flowing and very well written article
from an enormous amount of data. The article is indeed a pleasure to read and the microarray data is
presented in a clear and easily digestible manner. The article makes a substantial contribution to our
canon of knowledge concerning early events in embryonic and fetal testicular, ovarian, and adrenal gland
development. While it is able to corroborate earlier findings by others, it also provides an extensive
amount of new data and sheds light on species-dependent differences in organogenesis. Despite these
achievements, there are concerns that should be addressed in order to improve the quality of the data
and make the presented arguments more scientifically sound.
There are two major concerns that should be addressed to a satisfactory extent. Firstly, the main concern
of the manuscript is data validation. Novel findings based on microarray data should always be confirmed
using another method, such as qPCR and/or immunohistochemical staining (as the authors have done for
the adrenal data: Fig4 and Fig 5). At many points in the manuscript (p8, p11, p25, p27) the authors
propose that co-enrichment with known markers associated with distinct biological processes or
monogenic disorders validates the data. This is, however, at best merely correlative data and provides
only weak validation. It would greatly improve the quality of the research if the authors would validate the
data at least for the most important candidate genes using qPCR and/or immunohistochemistry. The
authors have included a good selection of immunohistochemical stainings but they are partially a cause
for concern in their own right (see below) plus fail to provide sufficient validation for the data. The latter
statement might sound harsh but in order to validate microarray data the authors need to provide at least
two stainings: one that shows low/no expression at a specific time point (say CITED1 in the early testis)
and high expression in another time point (CITED1 in late testis). Including this kind of data would be
sufficient to address this concern and would provide the minimum acceptable validation for the microarray
findings. Strictly speaking IHC does not validate microarray data as it visualizes proteins, not RNA, but at
the end it is the protein expression that we are interested in and in most cases microarray/RNAseq/qPCR
are just tools to identify the differentially expressed mRNAs that are translated into proteins.
The second major concern is the quality of immunohistochemical stainings. Particularly lack of negative
control stainings and difficulty to interpret the data due to inappropriate magnification and/or absence of
high magnification insets. Please include negative control stainings at least for the novel markers. Provide
high magnification inset for the following figures: Fig.4c top and middle panel, Fig.12c and Fig.12d. Due to
poor quality, please consider providing an alternative image of higher magnification or after cropping
(+inset) for Fig.12d and Fig.13d top panel. 
Minor points:
P8, left column, row 12 from top. For Figure 2c FC≥2 was used, whereas for 2d FC≥1. Therefore it
is a bit misleading to use term “…similar analysis…” in this case.
 
P8, right column, row 1 from top: check spelling.
 
Figure 5b. The number of samples included in the qPCR analysis is not mentioned and error bars
1 2
1
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Figure 5b. The number of samples included in the qPCR analysis is not mentioned and error bars
are not shown. The authors might also consider redrawing the scale for Y axis.
 
Related to referee question #5: Is the data presented in Figure 14b and 14c available somewhere
to have a look at the differentially expressed genes (cf. Figure 4b/Table 1)?
 
P26, left column, rows 5-7 from the bottom. The provided data only indicates that GRAMD1B and
RMDN2 are expressed in 9 wpc testis. Because only one time point was included in the analysis, it
does not demonstrate   of these genes/enhanced expression of the protein products,upregulation
as stated in the text.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
 No competing interests were disclosed.Competing Interests:
Referee Expertise: JT: developmental endocrinology, spermatogenesis; J-AM: stem cells,
spermatogenesis
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
Author Response 17 Oct 2017
, UCL GOS Institute of Child Health, UKJohn Achermann
We thank the reviewers for their constructive comments. We have addressed these as
shown in bold below and modified the revised manuscript accordingly. 
 
There are two major concerns that should be addressed to a satisfactory extent. Firstly, the main
concern of the manuscript is data validation. Novel findings based on microarray data should
always be confirmed using another method, such as qPCR and/or immunohistochemical staining
(as the authors have done for the adrenal data: Fig4 and Fig 5). At many points in the manuscript
(p8, p11, p25, p27) the authors propose that co-enrichment with known markers associated with
distinct biological processes or monogenic disorders validates the data. This is, however, at best
merely correlative data and provides only weak validation. It would greatly improve the quality of
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 distinct biological processes or monogenic disorders validates the data. This is, however, at best
merely correlative data and provides only weak validation. It would greatly improve the quality of
the research if the authors would validate the data at least for the most important candidate genes
using qPCRand/or immunohistochemistry. The authors have included a good selection of
immunohistochemical stainings but they are partially a cause for concern in their own right (see
below) plus fail to provide sufficient validation for the data. The latter statement might sound harsh
but in order to validate microarray data the authors need to provide at least two stainings: one that
shows low/no expression at a specific time point (say CITED1 in the early testis) and high
expression in another time point (CITED1 in late testis). Including this kind of data would be
sufficient to address this concern and would provide the minimum acceptable validation for the
microarray findings. Strictly speaking IHC does not validate microarray data as it visualizes
proteins, not RNA, but at the end it is the protein expression that we are interested in and in most
cases microarray/RNAseq/qPCR are just tools to identify the differentially expressed mRNAs that
are translated into proteins.
 
We agreed that further validation would be ideal at both the RNA level (qRTPCR) and
protein level (immunohistochemistry), but we tried to focus on the key new genes
described and were limited by the specificity of antibodies for IHC for some genes/protein
of interest. We did focus largely on IHC data as we felt this provided validation at the
protein level as well as RNA, but agree we could have included more validation across the
time series (some of which we omitted because of space).
 
To address these issues, we have:
 
1) Provided qRTPCR data for validation of key upregulated testis genes (CITED1,
ZNF280B, PRPS2, ANKRD18A) in the testis versus control samples. We also show
changes in expression level across three time points (CS18, CS23, 10 wpc). These data
are now shown as Supplementary Figure 1 and details have been added to the methods.
 
2) Provided qRTPCR data for upregulation of key novel steroidogenic components
(GRAMD1B, FOXO4, MAP3K15, RMDN2) across time points before and after the onset of
steroidogenesis (CS21, 8.5 wpc). These data are now shown as Supplementary Figure 2a
and details have been added to the methods.
 
3) Unfortunately we do not have IHC data for CITED1 across time, but we have shown
clear sequential upregulation by qRTPCR as described above (Supplementary Figure 1).
Furthermore, we have analysed available data from single-cell transcriptomics in human
gonad development recently published by Li  (Single-Cell RNA-Seq Analysis Mapset al.
Development of Human Germline Cells and Gonadal Niche Interactions. Li L, Dong J, Yan
L, Yong J, Liu X, Hu Y, Fan X, Wu X, Guo H, Wang X, Zhu X, Li R, Yan J, Wei Y, Zhao Y,
Wang W, Ren Y, Yuan P, Yan Z, Hu B, Guo F, Wen L, Tang F, Qiao J. Cell Stem Cell. 2017
Jun 1;20(6):858-873.e4. doi: 10.1016/j.stem.2017.03.007). We analysed all cells from 46,XY
embryos/foetuses between 4 and 19 weeks gestation that cover the time course of
interest (1207 single cells). Using a cut-off of >0.5 TPM to indicate expressed genes, we
found that 221/1014 [21%] of SOX9 negative cells co-expressed CITED1, whereas 97/193
[50%] of SOX9 positive cells co-expressed CITED1 (Chi-squared 66.2, df =1, p-value < 4e
). Furthermore, Cited1 was identified within developing Sertoli cells in recently
available data from mouse single-cell transcriptomics, with an expression time course
shortly after SOX9 (Deciphering cell lineage specification during male sex determination
with single-cell RNA sequencing. Stevant I, Neirijnck Y, Borel C, Escoffier J, Smith LB,
Antonarakis SE, Dermitzakis ET, Nef S.
-16
Page 33 of 42
Wellcome Open Research 2017, 2:25 Last updated: 08 NOV 2017
 Antonarakis SE, Dermitzakis ET, Nef S.
http://www.biorxiv.org/content/early/2017/09/18/190264). We feel that these are additional
novel, independent data to show the potential link between SOX9 and CITED1 in testis
development. 
 
4) We now provide sequential IHC data for GRAMD1B and RMDN2 before and after the
onset of steroidogenesis to show an increase in protein expression in the cytoplasm of
Leydig cells (Supplementary Figure 2b).
 
Please note that in the original manuscript we have included links to the Human Protein
Atlas for many key novel factors. This resource provides IHC data for adult tissues as well
as graphical data for qPCR datasets (e.g. FANTOM5, GTEx).
 
The second major concern is the quality of immunohistochemical stainings. Particularly lack of
negative control stainings and difficulty to interpret the data due to inappropriate magnification
and/or absence of high magnification insets. Please include negative control stainings at least for
the novel markers. Provide high magnification inset for the following figures: Fig.4c top and middle
panel, Fig.12c and Fig.12d. Due to poor quality, please consider providing an alternative image of
higher magnification or after cropping (+inset) for Fig.12d and Fig.13d top panel.
 
Negative control data are particularly important to assess binding of secondary
antibodies and non-specific effects. We include representative negative data in
Supplementary Figure 3b. Moreover, all of the IHC images shown include areas of
negative staining (e.g. capsule, non-endocrine tissue) which are important internal
negative controls for the primary antibody. 
 
The main aim of Fig. 4c (upper and middle panels) was to show the distribution of the
factors within the adrenal in general, but not in the capsule. Higher power magnification of
SF-1/NR5A1 in the adrenal gland is shown in Fig. 12c and in the new Supplementary
Figure 3a, but we feel that including it as an inset would be too crowded. 
 
We have included a higher power images of Fig. 12c (GRAMD1B, RMND2 in the adrenal
gland) in Supplementary Figure 3a. We have added a higher magnification image of
FOXO4 staining of nuclei into Figure 12d as an additional panel as requested, which
shows co-expression of FOXO4 and NR5A1 in nuclei of Leydig cells. Unfortunately we are
unable to provide a better quality image for 13d (upper panel) but a higher power
magnification is shown. 
 
 
Minor points:
P8, left column, row 12 from top. For Figure 2c FC≥2 was used, whereas for 2d FC≥1. Therefore it
is a bit misleading to use term “…similar analysis…” in this case.
 
We have changed this to “analysis”.
 
P8, right column, row 1 from top: check spelling.
 
We are unclear what this refers to.
 
Figure 5b. The number of samples included in the qPCR analysis is not mentioned and error bars
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 Figure 5b. The number of samples included in the qPCR analysis is not mentioned and error bars
are not shown. The authors might also consider redrawing the scale for Y axis.
 
We agree that these data should have been presented better. We have repeated the
experiment again three times in triplicate and present data with error bars. We have
replaced this part of the Figure 5b. 
 
Related to referee question #5: Is the data presented in Figure 14b and 14c available somewhere
to have a look at the differentially expressed genes (cf. Figure 4b/Table 1)?
 
We have uploaded this dataset into OSF as Dataset 7. We apologise that this was not
included.
 
P26, left column, rows 5-7 from the bottom. The provided data only indicates that GRAMD1B and
RMDN2 are expressed in 9 wpc testis. Because only one time point was included in the analysis, it
does not demonstrate upregulation of these genes/enhanced expression of the protein products,
as stated in the text.
 
We have now included qRTPCR and IHC to show up-regulation over time in
 Supplementary Figure 2a, b.
 No competing interests were disclosed.Competing Interests:
 24 April 2017Referee Report
doi:10.21956/wellcomeopenres.12140.r21686
  ,     Rodolfo A. Rey Romina P. Grinspon
 Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE) CONICET – FEI – División de
Endocrinología, Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina
 Departamento de Biología Celular, Histología, Embriología y Genética, Facultad de Medicina,
Universidad de Buenos Aires, Buenos Aires, Argentina
The comprehension of the mechanisms underlying adrenal and gonadal development in the first trimester
of intrauterine life is essential for the understanding of human congenital disorders. Most of the
information available on normal embryonic and fetal development of the adrenals and gonads derives
from studies in experimental models. This study provides crucial insight into the comprehension of these
developmental processes in humans. In fact, by performing microarray studies on tissues obtained from
accurately staged embryos and fetuses to assess time-series changes and differential expression
patterns, del Valle and colleagues have constructed an atlas of RNA expression in the adrenals, testes
and ovaries from 6 to 10 weeks post-conception, a critical period in the differentiation of these organs.
The authors validate their findings using quantitative RT-PCR and immunohistochemistry of genes known
to be important in adrenal and gonadal development. The expression profiles of known genes were
corroborated whereas unknown profiles of genes in the gonads and adrenals have been described.
These findings set the bases for a wide variety of future studies addressing the physiology and
pathophysiology of human adrenal and gonadal development.
 
We have minor comments:
1,2 1
1
2
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 We have minor comments:
Title and text: We have concerns about the use of the phrase “genomic atlas” in this study. In fact,
genomic atlases, e.g. cancer genome atlas, refer to the comprehensive description of variants of the
genome, whereas this work makes a comprehensive description of the transcripts present in the three
organs at different developmental stages. The phrases “transcriptomic atlas” or “atlas of gene expression”
(as used on page 5) seem more adequate.
 
Methods and Results: Carnegie and fetal stages are based on the morphological development of the
embryo, and are not directly dependent on either age or size. This concept should be more clearly
expressed (e.g. Supplementary Table 1 and text in Methods) in order to avoid that the non-specialised
reader interpret that there are precise cut-offs (e.g. CS18=44-47.5 days, etc.).
 
Methods and Results: Tissue transcriptome analysis by microarray is a powerful technique. Nonetheless,
like other techniques based on RNA extraction from whole tissue, one limitation is the confounding effect
due to modifications in RNA levels in single components whose relative proportion in the tissue varies or
differs. For instance, STAR was 73-fold higher in the adrenal tissue probably because most of the tissue
sample was composed of steroidogenic cells, whereas a similar amount of testis sample would only have
a few Leydig cells. This does not mean that one cortical adrenal cell expresses more STAR than one
Leydig cell. Or, if Sertoli cells represent 80% of testicular tissue on week 6 and 50% on week 10,
microarray results from whole testicular tissue will show a lower expression level of a given Sertoli cell
RNA even if each Sertoli cell expresses the same amount of the given RNA. This limitation should be
considered in the interpretation of the results: up/down-regulation give the idea of regulated
increase/decrease of a given RNA expression in one cell rather than increase/decrease of RNA levels in
whole tissue, which could be due to the relative proportion of cells expressing that given RNA. Therefore,
the words up-regulation and down-regulation may be misleading, and may need to be replaced (e.g.
“more/less abundant in whole testicular/ovarian/adrenal tissue”).
 
Methods: We do not have expertise to assess the BALT model used to pinpoint the time when gene
expression levels change. A mathematician/statistician should be consulted.
 
Results: We would have expected SRY and SOX9 to appear as a testis differentially expressed genes on
Figure 2. Could the authors discuss why they did not select them for this figure?
 
Figure 6: A differential expression of SRY on the adrenal is unexpected. Could the authors comment on
this?
 
Suppl. Table 1: there are two samples (Ovary CS21 and Testis CS18.2) with the same abnormal
karyotype translocation: 46,XX inv(9)(p11q13) and 46,XY inv(9)(p11q13) respectively. This a frequent
finding in infertile patients. Could the authors discuss this finding?
 
Discussion: page 25, “The role of SRY as the primary testis-determining gene has been known for 25
years, following transgenic mouse studies as well as the discovery of duplication of SRY in individuals
with 46,XX testicular disorders of sex development (DSD)”. Do the authors mean translocation of SRY, or
is it really duplication?
References
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 Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
Author Response 17 Oct 2017
, UCL GOS Institute of Child Health, UKJohn Achermann
We thank the reviewers for their positive and constructive comments. We have addressed
these as shown in bold below and modified the revised manuscript accordingly. 
 
Minor comments:
 
Title and text: We have concerns about the use of the phrase “genomic atlas” in this study. In fact,
genomic atlases, e.g. cancer genome atlas, refer to the comprehensive description of variants of
the genome, whereas this work makes a comprehensive description of the transcripts present in
the three organs at different developmental stages. The phrases “transcriptomic atlas” or “atlas of
gene expression” (as used on page 5) seem more adequate.
 
We agree that in the age of genome sequencing there might be confusion and that other
terms might be more accurate, but this term has been used to describe developmental
datasets before so we would prefer to leave the title as it is. 
 
Methods and Results: Carnegie and fetal stages are based on the morphological development of
the embryo, and are not directly dependent on either age or size. This concept should be more
clearly expressed (e.g. Supplementary Table 1 and text in Methods) in order to avoid that the
non-specialised reader interpret that there are precise cut-offs (e.g. CS18=44-47.5 days, etc.).
 
We have added a note in the methods to state that staging is based on morphological
characteristics.
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 characteristics.
 
Methods and Results: Tissue transcriptome analysis by microarray is a powerful technique.
Nonetheless, like other techniques based on RNA extraction from whole tissue, one limitation is
the confounding effect due to modifications in RNA levels in single components whose relative
proportion in the tissue varies or differs. For instance, STAR was 73-fold higher in the adrenal
tissue probably because most of the tissue sample was composed of steroidogenic cells, whereas
a similar amount of testis sample would only have a few Leydig cells. This does not mean that one
cortical adrenal cell expresses more STAR than one Leydig cell. Or, if Sertoli cells represent 80%
of testicular tissue on week 6 and 50% on week 10, microarray results from whole testicular tissue
will show a lower expression level of a given Sertoli cell RNA even if each Sertoli cell expresses the
same amount of the given RNA. This limitation should be considered in the interpretation of the
results: up/down-regulation give the idea of regulated increase/decrease of a given RNA
expression in one cell rather than increase/decrease of RNA levels in whole tissue, which could be
due to the relative proportion of cells expressing that given RNA. Therefore, the words
up-regulation and down-regulation may be misleading, and may need to be replaced (e.g.
“more/less abundant in whole testicular/ovarian/adrenal tissue”).
 
We have approached this study on the “whole tissue” level and talk about up-regulation
or down-regulation of genes in this regard. However, it is an important point to consider,
so we have added a paragraph in the discussion to address some of the limitations of this
work and included this point. 
 
Results: We would have expected SRY and SOX9 to appear as a testis differentially expressed
genes on Figure 2. Could the authors discuss why they did not select them for this figure?
 
We used a cut-off value of log2 FC >1 (i.e., two-fold) for this analysis and both factors
were just below. As can be seen in Fig. 6b and 8a even changes within the tissue are
subtle. 
 
Figure 6: A differential expression of SRY on the adrenal is unexpected. Could the authors
comment on this?
 
SRY may have some extra-gonadal expression, for example in the adrenal and brain. We
mentioned the potential role of SRY in the regulation of renin in the discussion. This is an
interesting area for future research. 
 
Suppl. Table 1: there are two samples (Ovary CS21 and Testis CS18.2) with the same abnormal
karyotype translocation: 46,XX inv(9)(p11q13) and 46,XY inv(9)(p11q13) respectively. This a
frequent finding in infertile patients. Could the authors discuss this finding?
 
The inv(9)(p11q13) balanced translocation is quite a common finding in the general
population (1.2-2.3%). Although data originally suggested this could be linked to
infertility, more recent publications have shown that differences in 1800 infertile people
were not statistically significantly higher (Association of pericentric inversion of
chromosome 9 and infertility in romanian population. Dana M, Stoian V. Maedica (Buchar).
2012 Jan;7(1):25-9; see also Heteromorphic variants of chromosome 9. Kosyakova et al.
Molecular Cytogenetics 2013;6:14). Several studies are also biased as this change can
increase with age and individuals being investigated for fertility were often older. There
were no specific outlying effects of these samples in our analysis, so we felt comfortable
including them in the dataset. 
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 including them in the dataset. 
 
Discussion: page 25, “The role of SRY as the primary testis-determining gene has been known for
25 years, following transgenic mouse studies as well as the discovery of duplication of SRY in
individuals with 46,XX testicular disorders of sex development (DSD)”. Do the authors mean
translocation of SRY, or is it really duplication?
 
. Thank you for identifying this mistake. We have changed it to translocation
 No competing interests were disclosed.Competing Interests:
 20 April 2017Referee Report
doi:10.21956/wellcomeopenres.12140.r21671
  ,   Andrew H. Sinclair Katie Ayers
Murdoch Children's Research Institute, Melbourne, VIC, Australia
The development of the adrenal glands and gonads represent two significant embryological events. The
development of both tissues is closely linked as they both derive from the same region of intermediate
mesoderm in early embryogenesis. Given this shared history it is not surprising that they share many
processes such as steroidogenesis in common. However, until the current study most of our
understanding of spatial and temporal gene expression profiles in these tissues has come from mouse
studies which are not always applicable to humans. This study by Achermann and colleagues finally
addresses this fundamental gap in our knowledge. The authors extracted RNA from adrenal, testis, ovary
and control tissues between 6-10 weeks   (wpc) in human embryos. The RNA was thenpost coitum
subjected to an Affymetrix array and subsequent differential gene expression analysis and mathematical
modelling to identify temporal changes across the dataset. In addition, they used pathway analysis and
confirmed the cellular localization of novel genes using immunohistochemistry.
The study confirmed the expression profiles of many known genes such as   and identified manyNR5A1
potential novel genes. Interestingly, they showed that the only protein coding Y-chromosome gene
detected in the developing human testis (CS18-CS22) was the   gene. Twenty-five years since theSRY
discovery of   as the sole primary testis determining factor we now have further proof in human tissueSRY
that this is the case. Novel components of the adrenal pathway have been identified as have genes that
are potentially up-regulated by   such as  ,   and  . In addition, potential novelSOX9 CITED1 ZNF280B PRPS2
genes were associated with adrenal and testicular steroidogenesis (eg.  ,  and  ).FOXO4 MAP3K15 RMND2
Of interest was the finding that while a similar number of differentially expressed genes were found in the
testis and ovary, pathway-enrichment analysis failed to reveal any annotated pathways in the later. The
study did reveal some interesting candidate ovarian genes such as   and  , some of whichOR10G9 OR4D5
appear to be involved in neurotransmission. This clearly highlights our lack of understanding of early
ovarian development, and suggests that additional methods may be required to find novel genetic
pathways important in this tissue.
The public availability of this data will be a great future resource for any researchers interested in human
adrenal or gonadal development. In addition, this database may allow researchers to isolate novel genes
involved in gonadal and adrenal disorders, many of which currently lack a defined genetic aetiology.
Finally, while the authors used a highly comprehensive set of tissues, expression analysis using
microarray platforms can have several drawbacks compared to technologies such as RNA-Seq.
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 microarray platforms can have several drawbacks compared to technologies such as RNA-Seq.
Microarrays have been shown to have poorer sensitivity for lowly-abundant RNA compared to RNA-Seq
and may also miss expression data for poorly annotated genes and alternative transcripts. We therefore
look forward to similar studies on human fetal adrenal and gonads using RNA-Seq and ultimately single
cell fate mapping approaches as have been achieved in mouse.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
Author Response 17 Oct 2017
, UCL GOS Institute of Child Health, UKJohn Achermann
We thank the reviewers for their positive comments and outlining some limitations. We
have addressed these as shown in bold below and modified the revised manuscript
accordingly. 
 
Finally, while the authors used a highly comprehensive set of tissues, expression analysis using
microarray platforms can have several drawbacks compared to technologies such as RNA-Seq.
Microarrays have been shown to have poorer sensitivity for lowly-abundant RNA compared to
RNA-Seq and may also miss expression data for poorly annotated genes and alternative
transcripts. We therefore look forward to similar studies on human fetal adrenal and gonads using
RNA-Seq and ultimately single cell fate mapping approaches as have been achieved in mouse.
 
These comments provide a very useful summary of potential drawbacks. We have
included a paragraph in the discussion outlining some limitations of the study and future
directions.
 No competing interests were disclosed.Competing Interests:
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 1.  
2.  
3.  
 19 April 2017Referee Report
doi:10.21956/wellcomeopenres.12140.r21958
 Olle Söder
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
This is well written, comprehensive and important work on the transcriptome of human embryonic and
fetal adrenal and gonad development. It is unique in its human focus and comparative approach on
adrenal, testis and ovary. Datasets and Supplementary material have been made generously available.
This reviewer has only a few comments to be considered.
 
The mathematical model and part of the statistics used are complex and not easy to follow for a
non-expert. It should therefore be reviewed by an expert statistician.
 
It is not entirely clear if data from XX adrenals were compared with data from XY adrenals and if
there was any difference.
 
In Fig. 13 D, lower part, SCUBE1 expression seems to be localized to flat cells in the periphery of
the chords. Have the authors considered that these cells may be peritubular cells (PTC) rather than
Sertoli cells or gonocytes?  PTC may be identified by their expression of aSma and PDGF-Ra. 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Reproductive physiology (basic science and clinical), testis biology, paediatric
endocrinlogy
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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 I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 17 Oct 2017
, UCL GOS Institute of Child Health, UKJohn Achermann
We thank the reviewers for their constructive comments. We have addressed these as
shown in bold below and modified the revised manuscript accordingly. 
 
This reviewer has only a few comments to be considered.
 
The mathematical model and part of the statistics used are complex and not easy to follow for a
non-expert. It should therefore be reviewed by an expert statistician.
 
Most of the statistics used for comparing expression between samples and heatmaps use
a standard R package. The model developed is also a fairly standard approach and similar
profiles were obtained using soft and hard clustering analysis (where genes can be
clustered to multiple or single clusters), but the model provided more detailed analysis
over time.
 
It is not entirely clear if data from XX adrenals were compared with data from XY adrenals and if
there was any difference.
 
The adrenal samples were intentionally chosen to be from 46,XY embryos/fetuses so that
they could be compared directly with testis without the complicating effects of any
sex-chromosome gene dosage. We agree that sex differences in extra gonadal tissues are
an interesting area to study but are beyond the scope of this manuscript. 
 
In Fig. 13 D, lower part, SCUBE1 expression seems to be localized to flat cells in the periphery of
the chords. Have the authors considered that these cells may be peritubular cells (PTC) rather than
Sertoli cells or gonocytes?  PTC may be identified by their expression of aSma and PDGF-Ra.
 
Thank you. At this stage of development the cells at the boundary of the cords are not
particularly flattened like classic peritubular myoid cells. Certainly the cells containing
SCUBE1 are fairly round and in some cases staining is seen throughout the cytoplasm
and in some more centrally positioned cells. As SCUBE1 is potentially a secreted protein
we wondered if the peripheral localisation was to do with this. However, we take the
reviewers point that these could be developing PTM cells. We have not been able to
address this further at present but will do so if we explore the role of SCUBE1 in the
future. 
 No competing interests were disclosed.Competing Interests:
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